TUC3PII-01_TU2670 Phase IIa Clinical Study
A Phase IIa, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Proof of Concept Study to Evaluate the Efficacy and Safety of Orally Administered TU2670 in Subjects With Mod to Severe Endometriosis-Associated Pain
Sponsor: TiumBio Co., Ltd.
This PHASE2 trial investigates Endometriosis and is currently completed. TiumBio Co., Ltd. leads this study, which shows 5 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
5 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
Status: Unknown → Completed
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Feb 2024 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2022 — Feb 2024 [monthly]
Recruiting PHASE2
First recorded
Aug 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- TiumBio Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Bialystok, Poland , Brno, Czechia , Bydgoszcz, Poland , Florence, Italy , Hradec Králové, Czechia , Ivano-Frankivsk, Ukraine , Katowice, Poland , Kiev, Ukraine , Kyiv, Ukraine , Lublin, Poland and 20 more locations